Mural Oncology plc
muraloncology.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q3 FY2025 10-Q, filed Nov 6, 2025. Its latest SEC filing is a SCHEDULE 13G/A from Dec 16, 2025.
10-Q for Q3 FY2025, filed Nov 6, 2025
The sections below describe the company as of the FY2024 annual report.
What Did They Do?
Develops investigational cytokine immunotherapies, including nemvaleukin, for patients with cancer.
10-K for FY2024, filed Mar 11, 2025
How Did They Make Money?
No revenue was reported.
10-K for FY2024, filed Mar 11, 2025
How Were They Changing?
- Net income
-
Sources
10-Q for Q3 FY2025, filed Nov 6, 2025
−$3.7MView ↗
- ▼ −88% (Loss)
- vs −$31.8M in Q3 FY2024
-
Dec 5, 2025
XOMA Royalty completed its acquisition of Mural Oncology
XRA 5 Corp., a subsidiary of XOMA Royalty, acquired Mural; its shares were delisted from Nasdaq.
Sources
8-K, filed Dec 5, 2025
WALTHAM, Mass. and DUBLIN, Ireland, December 5, 2025, (GLOBE NEWSWIRE) – Mural Oncology plc, (Nasdaq: MURA) (“Mural”) announces that the…View ↗
-
Apr 15, 2025
Mural stopped nemvaleukin development and began a strategic review
The board also approved a workforce reduction.
Sources
8-K, filed Apr 15, 2025
On April 14, 2025, the board of directors (the “Board”) of Mural Oncology plc (the “Company”) determined to discontinue all clinical…View ↗
-
Mar 25, 2025
ARTISTRY-7 failed its interim survival test, ending development for ovarian cancer
Mural said the trial would not continue to final analysis and it would cease nemvaleukin development for platinum-resistant ovarian cancer.
Sources
8-K, filed Mar 25, 2025
On March 25, 2025, Mural Oncology plc (the “Company”) announced that the ARTISTRY-7 phase 3 trial of nemvaleukin alfa in combination with…View ↗
Who Did They Compete With?
Competes with Anaveon, Ascendis, Cue Biopharma, Cullinan Oncology, Medicenna Therapeutics, Roche, Werewolf Therapeutics, Bristol-Myers Squibb, Iovance Biotherapeutics, Merck, Pfizer, Immunogen, Daiichi Sankyo, Bright Peak Therapeutics, Simcha Therapeutics, Gilead Sciences, Compugen, Amunix, DragonFly Therapeutics, and Moderna
10-K for FY2024, filed Mar 11, 2025Our lead product candidate nemvaleukin, if approved, may face competition from other IL-2-based cancer therapies. For example, Proleukin®…View ↗
Loading...
